TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03565796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized active referral plus financial incentive
Description: Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning leaflet
Description: The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans
Study: NCT04483778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Description: Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: SCRI-CARB7H3(s)x19 plus pembrolizumab
Study: NCT04922684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mimic facial expressions
Description: 16 times (4 times a week, last 4 weeks) of mimicking facial expressions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mimic facial expressions
Description: 16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
Study: NCT01947478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-2113 Drug-Eluting Balloon
Description: Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard angioplasty balloon
Description: Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
Study: NCT05855616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group chlorhexidine dressing
Description: Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.

Intervention type: OTHER
Group type: OTHER
Intervention: Group solution
Description: Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
Study: NCT02251119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Study: NCT05334355

Intervention type: OTHER
Intervention: Family history of hypertension
Description: Presence or absence of a family history of hypertension in a cross sectional study design.
Study: NCT03916991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Hip focused Neuromuscular Activation Exercise

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Hip focused Neuromuscular Activation Exercise
Study: NCT01617200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
Study: NCT04535752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX009
Description: Single or multiple ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX009
Description: Single or multiple ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple ascending dose
Study: NCT05052242

Intervention type: DIAGNOSTIC_TEST
Intervention: primary angle closure disease
Description: 2 swept source OCT biometers, IOL Master700 and Anterion
Study: NCT03065595

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ophiochepalus striatus extract
Description: each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
Study: NCT03169920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified-Minimally Invasive Surgical Technique + PRF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified-Minimally Invasive Surgical Technique
Study: NCT00730054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil+clonidine
Description: iv Remifentanil+ iv clonidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil+clonidine
Description: iv Remifentanil+ iv clonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil+clonidine
Description: iv Remifentanil+ iv clonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil+clonidine
Description: iv Remifentanil+ iv clonidine
Study: NCT02167542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Positive Pressure Ventilation
Description: Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2\>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP valve (Boussignac)
Description: Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2\>92%.
Study: NCT03331380

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan - obj 1
Description: For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without and some with administration of intravenous gadolinium based contrast agents (GBCAs).

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scans - obj 2
Description: For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
Study: NCT01617200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Asenapine
Description: 2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: 15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: 15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Olanzapine
Description: 15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
Study: NCT03565796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH booklet
Description: A general smoking cessation self-help booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH booklet
Description: A general smoking cessation self-help booklet
Study: NCT01617200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: 15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
Study: NCT00736424

Intervention type: DEVICE
Intervention: Itrel II™ and Soletra™ Epilepsy Control System
Description: Bilateral neurostimulation of the anterior nucleus of the thalamus
Study: NCT03884959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem Infusion
Description: HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
Study: NCT03142178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 3VM1001 active 2g Cream 3 times daily
Description: 3VM1001 2g Cream with active ingredient administered 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 3VM1001 active 3g Cream 3 times daily
Description: 3VM1001 3g Cream with active ingredient administered 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 3VM1001 active 3g Cream 4 times daily
Description: 3VM1001 3g Cream with active ingredient administered 4 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 3VM1001 vehicle 2g Cream 3 times daily
Description: 3VM1001 placebo 2g vehicle Cream administered 3 times daily
Study: NCT00965055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10 mg
Study: NCT03142178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 3VM1001 vehicle 3g Cream 3 times daily
Description: 3VM1001 placebo 3g vehicle Cream administered 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 3VM1001 vehicle 3g Cream 4 times daily
Description: 3VM1001 placebo 3g vehicle Cream administered 4 times daily
Study: NCT02225561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmaco- mechanical optimization
Description: Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~* Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~* The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~* Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical optimization only
Description: Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
Study: NCT02362269

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
Study: NCT00431769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
Study: NCT00965055

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period
Study: NCT02573753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Study: NCT02560909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLUAD® influenza vaccine
Description: MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUVIRAL®
Description: Standard 2015-2016 nonadjuvanted vaccine
Study: NCT02573753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight gain
Study: NCT05075902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
Study: NCT02002091

Intervention type: OTHER
Intervention: no specific treatment
Description: lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
Study: NCT01728753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1800 mg BID on Day 1, then 800mg BID for Days 2 5
Study: NCT01855048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-Rephasin® SAL200
Description: continuous intravenous infusion over 60 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INT200-Placebo
Description: Formulation buffer for continuous intravenous infusion over 60 minutes
Study: NCT00775788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting to Breasts
Description: Fat injection of Fat to breasts
Study: NCT01464463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT - active
Description: Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT - euthymic
Description: Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBASP
Description: Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship.
Study: NCT02317536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnipure Product 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnipure Product 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01756066

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Different levels of cost sharing
Study: NCT03331380

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scans - obj 3
Description: For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.